CompletedPhase 4NCT02245841

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

Studying Dermatomyositis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Cleveland Clinic
Principal Investigator
Anthony P Fernandez, MD, PhD
The Cleveland Clinic
Intervention
H.P. Acthar Gel(drug)
Enrollment
19 enrolled
Eligibility
18 years · All sexes
Timeline
2015 – 2021

Study locations (1)

Collaborators

Mallinckrodt

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02245841 on ClinicalTrials.gov

Other trials for Dermatomyositis

Additional recruiting or active studies for the same condition.

See all trials for Dermatomyositis →

← Back to all trials